Company overview

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and has made significant advancements in multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain — and continues to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Our global headquarters is in Boston, and we have research and development (R&D) sites and commercial offices worldwide.Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards.Read our community guidelines: https://www.vrtx.com/vertexs-community-guidelines/
Founded in 1989
Boston, Massachusetts, USA
6.1K employees (282 in marketing)
83% recommend to a friend
92% positive business outlook

Salaries

Typical salary range

$158,800 – $238,100

/ yr

Help build salary transparency at Vertex Pharmaceuticals

Share your compensation anonymously to see full data.

Contribute

People

Hiring activity

Open marketing jobs over time

36 open now

Headcount trend

Company growth over the last 12 months

Headcount -1.3% year over year

Funding

Total funding

$657.3M

Last raise

$1.1M

Post IPO Secondary, 2 years ago

Funding history

Jul 2024

Post IPO Secondary Vertex Pharmaceuticals · $1.1M

May 2022

Post IPO Equity Vertex Pharmaceuticals · $50M

Dec 2009

Post IPO Equity Vertex Pharmaceuticals · $443M

Sep 2009

Post IPO Debt Vertex Pharmaceuticals · $120M

Sep 2009

Post IPO Equity Vertex Pharmaceuticals · $35M

Mar 2009

Post IPO Equity Vertex Pharmaceuticals · $2.4M

Audience

Monthly website visitors
340.5K
Month over month-13%
Quarter over quarter-3.3%
Top sourceDirect (38.5%)
Ad budget per month$44.9K
Average search rank56.7
Traffic source mix
Direct
38.5%
Search
36.6%
Referral
22.7%
Paid referral
1.1%
Social
1%

LinkedIn followers

Follower count and growth

Total followers

570.7K

12-mo growth

Monthly growth

+2.9%

News

Links